skinny.

Latest / Taylor Tailored

Ozempic vs Mounjaro: What The New Heart-Risk Study Really Found

A huge new real-world study has added another twist to the Ozempic-versus-Mounjaro debate. Researchers examined healthcare data from more than 636,000 adults with type 2 diabetes and found that patients who increased semaglutide from 1 mg to 2 mg had a statistically significant 6 per cent lower risk of major cardiovascular events than those who switched to tirzepatide.

But that headline needs context. This was not a randomised head-to-head cardiovascular trial, and other recent studies comparing semaglutide with tirzepatide have reached different conclusions.

This episode explains what…

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.